J&J's Mixed Phase III Data For Esketamine Highlight Challenges In Resistant Depression

 
• By Jessica Merrill

J&J released data from the first two Phase III trials testing esketamine in patients with treatment-resistant depression, but only one study met the primary efficacy endpoint.

magnetic resonance image (MRI) of the brain human

More from Clinical Trials

More from R&D